GILD

Gilead Sciences

Halal Rating :
Comfortable
See Details
Last Price $88.39 Last updated:
Market Cap $110.58b
7D Change -8.47%
1 Year Change 18.61%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange Nasdaq
Next Earnings Date Nov. 7, 2024

Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $7.54b $6.89b - $238.0m 0.00% 3.45%
June 30, 2024 $6.95b $4.55b - $237.0m 0.00% 5.21%
March 31, 2024 $6.69b $11.26b - $254.0m 0.00% 2.26%

Company Impact

Help us evaluate Gilead Sciences's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Justification for our Halal Rating

Contribute

Recent News & Updates